Abstract: Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.

Abstract: A bit rate control method and device is disclosed. The method comprises: obtaining a bit rate control mode and coding control parameters of a current short period in a long period, determining a frame-level coding parameter of the current short period, and transmitting the frame-level coding parameter to an encoder; obtaining second bit stream information sent by the encoder; performing statistical analysis according to the second bit stream information to obtain statistical information including complexity information of the current video frame, the number of the encoded bits in the current short period, and coding quality information of the current short period; when the long period has not ended and if the current short period has ended, obtaining a period length of the current short period, the preset bit rate control parameters and the statistical information, and determining an average bit rate.

Abstract: Systems, devices and methods are provided for video encoding and decoding. An example method includes: analyzing one or more input images; obtaining a background image from the one or more input images; encoding the background image to obtain a background frame; decoding the background frame to obtain a reconstructed image of the background frame; obtaining a first image from the one or more input images; encoding at least partially the first image to obtain a refreshment frame based at least in part on a difference between the first image and the reconstructed image of the background frame; obtaining a second image from the one or more input images; encoding at least partially the second image to obtain a common frame; and generating a video bit stream based at least in part on the background frame, the refreshment frame and the common frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: When performing an inter predictive encoding on any image frame x is required, a reference image frame is determined for image x; image x is a P-frame image or a B-frame image; for each reference image frame, following processes are respectively performed: whether resolution of a reference image frame is the same as resolution of image x is determined; if resolution of the reference image frame is different from resolution of image x, resolution of reference image frame is adjusted to be the same as resolution of image x; if resolution of each reference image frame is the same as resolution of image x, inter predictive encoding is performed on image x based on each reference image frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: Systems, devices and methods are provided for video encoding and decoding. An example method includes: analyzing one or more input images; obtaining a background image from the one or more input images; encoding the background image to obtain a background frame; decoding the background frame to obtain a reconstructed image of the background frame; obtaining a first image from the one or more input images; encoding at least partially the first image to obtain a refreshment frame based at least in part on a difference between the first image and the reconstructed image of the background frame; obtaining a second image from the one or more input images; encoding at least partially the second image to obtain a common frame; and generating a video bit stream based at least in part on the background frame, the refreshment frame and the common frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.

Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.